Key result
Therapeutics for acute coronary syndromes have undergone remarkable changes over the past 20 years that have benefited patients with these conditions.
Key points are not available for this paper at this time.
As a student of therapeutics for acute coronary syn-dromes (ACS) for more than 20 years, I have beengratified to see the remarkable changes that have benefited patients with these syndromes, which represent the leading cause of death and disability in technologically
No takes yet. Share an insight, caveat, or question.
Robert M. Califf (2003) studied this question. Therapeutics for acute coronary syndromes have undergone remarkable changes over the past 20 years that have benefited patients with these conditions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: